Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies is facing a challenging capital environment with a recent $2.0M registered direct financing, leading the financial analyst to lower the stock rating from Buy to Hold. However, the company's partnership with AbbVie for their dermal filler and the potential for positive data or regulatory advances for their own regenerative candidates provide potential catalysts for improved market outlook and cashflow. Despite de minimis revenues and a reduction in operating expenses, CollPlant holds a solid cash balance of $8.5M as of September 30, 2025.

Bears say

CollPlant Biotechnologies is highly reliant on its partnership with AbbVie to develop and commercialize its proprietary rhCollagen product, posing a significant risk if the collaboration is unsuccessful or does not result in high demand for its products. The company also faces significant risks in clinical and regulatory processes, competition in the market, and potential legal and intellectual property issues, which could hinder its growth and profitability. Additionally, decreasing revenues and a tight cost base signal potential financial difficulties in the near-term.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.